Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Samba TV Announces Acquisition of Semasio, Strengthening its Position in Contextual Targeting
-
Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy in Advanced Colorectal Cancer
-
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
-
CalypsoAI Recognized as One of the Most Important VC-backed Cybersecurity Companies of 2024 on Fortune’s Cyber 60 List
-
Brightspeed Donates $25,000 for Storm Relief, Continues On-the-Ground Support
-
Duda Agency Expands Partnership with Bridgeline’s WooRank
-
Opening of new mortgage covered bonds (SDRO) financing FlexLån®
-
New Treatments, Novel Research Drive Better Survival Rates for Canadians with Lung Cancer, Offering Hope to Thousands: Lung Health Foundation
-
Hexagon Purus ASA: Mandatory notification of trade
-
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
-
Edesa Biotech’s Founder Makes Strategic Investment in the Company
-
Worksport Ltd. Unveils Upgraded SOLIS Technology, Enhancing Solar Tonneau Covers for Broader Market Reach
-
Ocean Power Technologies Secures Follow-On Order for WAM-V 8 and Delivers WAM-V 16 and WAM-V 22 to Latin America
-
Adam Stewart Appointed to Vivid Seats’ Board of Directors
-
Form 8.3 - Learning Technologies Group Plc
-
Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
-
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
-
Dragon Interact, a Subsidiary of DatChat, To Launch "Trump Trivia" - A New AI-Generated Podcast for the Ultimate Political Trivia Experience
-
Dragon Interact, a Subsidiary of DatChat, To Launch "Trump Trivia" - A New AI-Generated Podcast for the Ultimate Political Trivia Experience
-
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alz
-
Finance Leaders Gaining Substantial Benefits from AP Automation, But Opportunities Remain to Do More
-
Bybit Powered by SATOS Reaffirms Regulatory Compliance and Future Growth in the Netherlands
-
MaxCyte to Participate in Two Upcoming Investor Conferences
-
Euro Sun Mining and Glencore Enter into MOU for Concentrate Offtake
-
Nanox Highlighted on TIME's Best Inventions of 2024 List for its AI Solutions
-
Standard BioTools to Participate in Upcoming Investor Conferences
-
Uniti Group Inc. Reports Third Quarter 2024 Results
-
Nanox Highlighted on TIME's Best Inventions of 2024 List for its AI Solutions
-
Greif, Inc. Announces 2024 Fourth Quarter Earnings Release and Conference Call Dates
-
FlexShopper and PayPossible Expand Consumer Payment Options Through Strategic Partnership
-
Woodward Schedules Fiscal 2024 Fourth Quarter and Full Year Earnings Release and Conference Call
-
OpenTable and Visa Team Up to Offer Exclusive Dining Access in Canada
-
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
-
First Mid Bancshares, Inc. Announces Third Quarter 2024 Results
-
EBYH Broadcasts Media Kit for the Inaugural 1-Million Strong Killing Cancers, Fight Club, VIP Fundraiser Event, Pre-Sales for Event Sponsorships and VIP Tickets, Final Venue Choice and Inaugural Event
-
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
-
Reviva to Participate in the UBS Global Healthcare Conference
-
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
-
U.S. Energy Corp. Announces Major Helium Discovery from Initial Development Program
-
Integral Metals Corp. Announces Listing of Common Shares on the CSE
-
Sow Good to Hold Third Quarter 2024 Conference Call on Thursday, November 14, 2024 at 10:00 a.m. ET
-
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
-
Global Uranium Corp. Completes Survey Work on Wyoming Claims, Collecting Radiometric and Drone Imagery Data
-
Recce Pharmaceuticals Announces Interim Efficacy Data and Safety Approval for Phase II ABSSSI Clinical Trial
-
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
-
The ALS Society of Canada celebrates $13 million investment into Ontario Provincial ALS Program
-
Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer
-
Nuwellis Welcomes University of Iowa Health Care Stead Family Children’s Hospital as Newest Pediatric Customer
-
Bionano Announces $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Inovalon’s Converged Quality Solution Customers Realized a 5% Increase in Star Ratings Score, Including Nearly 60% of All Medicare Health Plans Which Received CMS’ Highest 5-Star Rating

